BioMarin Pharmaceutical Культура компании

Mr. Jeffrey Robert Ajer, also known as Jeff, has been the Chief Commercial Officer of BioMarin Pharmaceutical Inc. since October 2012. Mr. Ajer has been an Executive Vice President of BioMarin Pharmaceutical Inc. since December 19, 2013 and served as its Senior Vice President since October 2012 until January 2014. He served as Vice President of Commercial Operations The Americas at BioMarin Pharmaceutical Inc. since April 2009 until October 2012. He joined BioMarin in September 2005 as Vice President of Sales and Marketing Operations since September 2005 until 2009. He has over 25 years of experience in the pharmaceutical and biotech industry, with expertise in rare disease and specialty medicine, sales and marketing management, domestic and international business and operational and corporate leadership. From November 2003 to August 2005, Mr. Ajer worked at Genzyme Corporation where he served as Vice President, Global Transplant Operations. In this role, Mr. Ajer developed capabilities and represented the business unit's objectives in numerous areas including long range planning, sales operations, global distribution and customer service and global pricing and contracting. He served as Senior Director of Sales Operations, Bids and Contracts for SangStat Medical Corporation until the company's 2003 acquisition by Genzyme. From June 1986 to July 1999, Mr. Ajer held positions with increasing responsibility at ICN Pharmaceuticals, Inc., including Director, Marketing and Sales Services and Director, Purchasing Worldwide. He has been an Independent Director at Nektar Therapeutics since September 21, 2017. He has been Independent Director at True North Therapeutics, Inc. since February 1, 2017. Mr. Ajer received both a B.S. in Chemistry and an M.B.A. from the University of California, Irvine.

Mr. George Eric Davis has been an Executive Vice President at BioMarin Pharmaceutical Inc. since December 30, 2015 and has been its General Counsel and Secretary since 2004. Mr. Davis served as Senior Vice President at BioMarin Pharmaceutical Inc. from December 2005 to March 2016. Mr. Davis served as an Assistant Secretary of BioMarin Pharmaceutical Inc. and served as its Vice President from 2004 to December 2005. He joined Biomarin Pharmaceutical Inc. in March 2004. From 2000 to 2004, he worked in the San Francisco office of Paul Hastings, Janofsky & Walker LLP, where he was an associate in the Corporate Department and served on its national securities practice committee. He serves as a Member of Supervisory Board at Prosensa Holding N.V. Mr. Davis received a B.A from the University of California, Berkeley and a J.D. from the University of San Francisco.

Dr. Elaine J. Heron, Ph.D., served as the Chairman of Labcyte Inc. and served as its Chief Executive Officer July 2001 to September, 2008. Dr. Heron joined Labcyte in July 2001. She served as General Manager of the Molecular Biology Division at Applied Biosystems and Corporate Vice President of Applera, the parent of Applied Biosystems. This division was responsible for all DNA products including sequencers, PCR, arrays, forensics and diagnostics. Prior to serving as a General Manager, she was responsible for worldwide sales, service and support. Dr. Heron was also the Vice President of Marketing for Affymetrix and a Founder of Molecular Dynamics, which is now a division of GE Healthcare. She has been an Independent Director of BioMarin Pharmaceutical Inc. since July 2002. She served as a Director at Fluxion Biosciences, Inc. She is also a Member of the Biotech Investment Committee at Life Science Angels, Inc. Previously, she served as a Director at Glyko Biomedical Ltd. Dr. Heron holds a B.S. and a Ph.D. in Chemistry from Purdue University and an MBA from the Presidential/Key Executive Program at Pepperdine University.

Dr. Robert A. Baffi, Ph.D., MBA, serves as an Executive Vice President of Technical Operations at BioMarin Pharmaceutical Inc. Dr. Baffi is responsible for overseeing BioMarin's manufacturing, process development, quality, analytical chemistry & logistics departments. He served as the Chief Technology Officer of BioMarin Pharmaceutical Inc. since 2000. He served as Senior Vice President of Technical Operations at BioMarin Pharmaceutical Inc. from 2000 to December 2009 , having joined BioMarin in May 2000 and previously served as Vice President of Quality & Analytical Chemistry since January 2002. From February 1986 to May 2000, Dr. Baffi served in a number of progressively more responsible positions at Genentech, Inc. Prior to Genentech, he worked for Cooper BioMedical as a Research Scientist and at Becton Dickinson Research Center as a post-doctoral fellow. He has contributed to more than 20 major regulatory submissions for product approval in the United States and Europe and to more than 50 regulatory submissions for investigational new drug testing. He serves as a Member of Supervisory Board of Prosensa Holding N.V. He served as a Director of KaloBios Pharmaceuticals, Inc. from December 1, 2014 to November 19, 2015. Dr. Baffi received a Ph.D. in biochemistry as well as an M.Phil. and a B.S. in biochemistry from the City University of New York and an M.B.A. from Regis University.

Mr. Daniel K. Spiegelman, also known as Dan, B.A., M.B.A. serves as the Chief Financial Officer and Executive Vice President at BioMarin Pharmaceutical Inc. Mr. Spiegelman is the founder of Rapidscan Pharma Solutions, Inc. and served as its Director. From May 2009 to May 2012, he served as a strategic and financial consultant to a portfolio of public and private life science companies. He served as the Chief Financial Officer of CV Therapeutics Inc., from January 1998 to May 2009 and its Senior Vice President until May 2009. He was the Principal Accounting Officer of CV Therapeutics Inc. He joined CV Therapeutics in January 1998 and served as its Vice President from January 1998 to September 1999. He co-founded Rapidscan Pharma Solutions, Inc., in 2010 and serves as its Chief Executive Officer. He served as the Chief Financial Officer and Senior Vice President of Gilead Palo Alto, Inc. since September 1999 and served as its Principal Accounting Officer. Mr. Spiegelman has over 25 years of executive management, finance and operations experience. Mr. Spiegelman was also employed by Genentech, Inc. since 1991 and served as its Treasurer from 1996 to 1998, Assistant Treasurer from 1992 to 1996 and Treasury Manager from 1991 to 1992. He has been the Chairman of the Board and Director of Relypsa, Inc. since June 19, 2014. He has been an Independent Director at Cascadian Therapeutics, Inc. since June 2008. He serves as a Director of Rapidscan Pharma Solutions, Inc. He served as a Director at Anthera Pharmaceuticals, Inc., from February 2010 to June 23, 2014; Affymax, Inc., since October 6, 2006 and Omeros Corporation from December 2009 to June 21, 2012. He served as an Independent Director of Xcyte Therapies Inc. from September 8, 2004 to 2006. He served as a Director at Cyclacel Pharmaceuticals Inc., from September 2004 to June 2012. He served as a Director of Jennerex Biotherapeutics Inc. Mr. Spiegelman holds a B.A. in Economics from the Stanford University and an MBA from Stanford Graduate School of Business.

Mr. Brian R. Mueller has been the Chief Accounting Officer of BioMarin Pharmaceutical Inc. since March 2, 2011 and serves as its Group Vice President. Mr. Mueller has been a Corporate Controller of BioMarin Pharmaceutical Inc. since July 2007 and served as its Vice President from March 2009 to March 2014. He joined BioMarin in December 2002. Prior to joining BioMarin, he worked in the San Francisco office of KPMG LLP as a Senior Manager in its audit practice. He joined KPMG LLP in June 2002 and served at Arthur Andersen LLP in its Audit and Business Advisory services practices in Chicago and San Francisco. His public accounting experience includes accounting, audit and business advisory services for both domestic and multi-national publicly held companies within a variety of industries, primarily manufacturing and consumer products. He has been a Director of Anthera Pharmaceuticals, Inc. since June 23, 2014. He is a Member of the American Institute of Certified Public Accountants. Mr. Mueller received a B.S. in Accountancy from Northern Illinois University in DeKalb, Illinois.

Mr. Philip Lo Scalzo serves as Chief Compliance Officer and Senior Vice President of BioMarin Pharmaceutical Inc. Mr. Scalzo served as Vice President of Corporate Compliance & Ethics and Corporate Compliance Officer of BioMarin Pharmaceutical Inc. Mr. Scalzo joined BioMarin Pharmaceutical Inc. in 2007. He is responsible for creating and maintaining the BioMarin Pharmaceutical's global compliance program and overseeing its internal audit function. His responsibilities include: chairing the Corporate Compliance Committee; overseeing the development and implementation of corporate compliance policies; training employees and partners; scoping and executing internal audits, including audits of third-party vendors; coordinating enterprise risk assessments and analysis; monitoring promotional events and other interactions with healthcare professionals; managing investigations; and implementing corrective actions. Prior to this role, he served as BioMarin's Deputy General Counsel, responsible for a variety of legal and corporate compliance-related matters. Before joining BioMarin, he spent four years at Sanofi-Aventis where he served as an Assistant General Counsel supporting the organization's cardiovascular operations team, corporate compliance department, litigation and human resources groups. Prior to joining Sanofi-Aventis, he was an Associate Attorney in the New York office of Sedgwick, Detert, Moran & Arnold where his practice primarily focused on defending pharmaceutical product liability cases. Mr. Scalzo received a J.D. from Brooklyn Law School and a B.A. in History from Boston College.

Jeff Ajer serves as the Executive Vice President, Chief Commercial Officer of BioMarin Pharmaceutical Inc.. Jeff started at BioMarin Pharmaceutical Inc. in September of 2012. Jeff currently resides in the San Francisco Bay Area.

Dan Spiegelman serves as the Executive Vice President, Chief Financial Officer of BioMarin Pharmaceutical Inc.. Dan started at BioMarin Pharmaceutical Inc. in May of 2012. Dan currently resides in the San Francisco Bay Area.